Thursday, September 09, 2021 8:21:56 AM
Source: PR Newswire (US)
NAPLES, Fla., Sept. 9, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that Dr. Joseph Tucker, MagicMed Industries' ("MagicMed") Chief Executive Officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference and Virtual Gravitas Health Reimagined Investor Day.
Dr. Tucker's H.C. Wainwright 23rd Annual Global Investment Conference presentation will be available on-demand beginning Monday, September 13th at 7:00 a.m. ET. To attend please register here.
Dr. Tucker is also scheduled to present on Thursday, September 16th at 10:00 a.m. PT / 1:00 p.m. ET at the Virtual Gravitas Health Reimagined Investor Day. To register for the event please use the following LINK.
On May 24, 2021, Enveric Biosciences announced the definitive agreement to acquire MagicMed Industries. Enveric and MagicMed will each hold a meeting of their respective stockholders. The Enveric annual meeting will be held virtually on September 14, 2021 at 10:00 a.m., Eastern Time, at www.virtualshareholdermeeting.com/ENVB2021.
For more information about each conference or to schedule a one-on-one meeting with MagicMed's management team, please contact your appropriate H.C. Wainwright or Gravitas representative directly, or KCSA Strategic Communications at EnvericBio@kcsa.com.
About the H.C. Wainwright 23rd Annual Global Investment Conference
H.C. Wainwright & Co. is hosting its 23rd Annual Global Investment Conference, which is being held as a virtual event from September 13-15, 2021. A record-setting number of participants are expected to view the 850+ company presentations scheduled as live feed or available as recorded for this year's edition of the H.C. Wainwright Global Investment Conference.
The conference offers six sector tracks devoted to Healthcare & Biotech, Metals & Mining, Cryptocurrency, Blockchain & FinTech, CleanTech, Technology, Media & Telecommunications and Shipping & Maritime.
The daily format includes corporate presentations, investor one-on-one meetings, topical presentations by keynote speakers and virtual evening events to encourage informal interaction amongst conference participants. The annual conference is a "must see" event for institutional investors of all types, private equity firms, venture capitalists, industry executives and business development executives.
About the Gravitas Health Reimagined Investor Day
This year's Gravitas Health Reimagined Investor Day will feature several leaders in the healthcare space and will be attended virtually by institutional and retail investors from North America and abroad. For additional details about the conference and Gravitas Securities Inc., please visit: www.gravitassecurities.com
About Enveric Biosciences
Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients. Initial indications include radiodermatitis, a common and often severe side effect of radiation therapy, and chemotherapy-induced neuropathy. For more information, please visit https://www.enveric.com/.
About MagicMed
MagicMed Industries intends to partner with pharmaceutical and other companies to develop and commercialize psychedelic-derived pharmaceutical candidates. MagicMed's psychedelic derivatives library, the Psybrary™, is anticipated to be an essential building block from which industry can develop new patented products. The initial focus of the Psybrary™ is on psilocybin and DMT derivatives, and it is then expected to be expanded to other psychedelics such as MDMA, LSD, mescaline, and ibogaine. For more information, please visit https://www.magicmedindustries.com/.
Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
valter@kcsa.com / asoss@kcsa.com
Media Contacts
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
212.896.1241 / 212.896.1204
ckasunich@kcsa.com / rcona@kcsa.com
MagicMed Industries Contact
Natalie Dolphin
Director of Marketing
ndolphin@magicmedindustries.com
Cision View original content:https://www.prnewswire.com
Recent ENVB News
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 09/12/2024 01:35:30 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/12/2024 04:15:08 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 09/04/2024 10:43:27 PM
- Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 09/04/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/22/2024 12:00:16 PM
- Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions • Business Wire • 08/13/2024 12:00:00 PM
- Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results • Business Wire • 08/12/2024 09:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 09:13:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 09:05:46 PM
- Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally • Business Wire • 07/25/2024 12:00:00 PM
- Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement • Business Wire • 07/15/2024 01:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 12:00:39 PM
- Enveric Biosciences Announces Patent Granted for Drug Candidate • Business Wire • 07/10/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/08/2024 09:10:29 PM
- Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate • Business Wire • 06/25/2024 12:00:00 PM
- Enveric Biosciences to Participate in BIO International Convention 2024 • Business Wire • 05/30/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 08:15:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 12:00:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 09:25:22 PM
- Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results • Business Wire • 05/15/2024 10:00:00 AM
- Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders • Business Wire • 05/14/2024 12:00:00 PM
- Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids • Business Wire • 05/08/2024 11:00:00 AM
- Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023 • Business Wire • 03/26/2024 11:00:00 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM